JP2022516170A5 - - Google Patents
Info
- Publication number
- JP2022516170A5 JP2022516170A5 JP2021538752A JP2021538752A JP2022516170A5 JP 2022516170 A5 JP2022516170 A5 JP 2022516170A5 JP 2021538752 A JP2021538752 A JP 2021538752A JP 2021538752 A JP2021538752 A JP 2021538752A JP 2022516170 A5 JP2022516170 A5 JP 2022516170A5
- Authority
- JP
- Japan
- Prior art keywords
- labeled
- composition
- cells
- parp inhibitor
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962788206P | 2019-01-04 | 2019-01-04 | |
| US62/788,206 | 2019-01-04 | ||
| PCT/US2020/012016 WO2020142583A1 (en) | 2019-01-04 | 2020-01-02 | Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022516170A JP2022516170A (ja) | 2022-02-24 |
| JP2022516170A5 true JP2022516170A5 (enExample) | 2023-01-19 |
Family
ID=71406723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021538752A Pending JP2022516170A (ja) | 2019-01-04 | 2020-01-02 | Ｐａｒｐインヒビターおよび抗体放射性物質結合体の組み合わせを使用してがんを処置するための方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20220072167A1 (enExample) |
| EP (1) | EP3906061A4 (enExample) |
| JP (1) | JP2022516170A (enExample) |
| CA (1) | CA3125197A1 (enExample) |
| WO (1) | WO2020142583A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220275090A1 (en) * | 2021-02-22 | 2022-09-01 | Janssen Biotech, Inc. | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors |
| EP4319729A4 (en) * | 2021-04-09 | 2025-02-26 | Cardiff Oncology, Inc. | CANCER TREATMENT WITH PARP INHIBITORS AND PLK1 INHIBITORS |
| EP4209217A1 (en) * | 2022-01-11 | 2023-07-12 | Fundación Profesor Novoa Santos | Method for the treatment of brca1/2 mutated cancer |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| WO2024263637A1 (en) * | 2023-06-20 | 2024-12-26 | The Regents Of The University Of California | Combination therapy with peptide receptor radionuclide and dna repair inhibitor |
| CN116726187B (zh) * | 2023-07-26 | 2025-09-30 | 珠海市人民医院 | 一种小分子配体-鲁卡帕尼偶联物及其制备方法 |
| CN117180277A (zh) * | 2023-08-04 | 2023-12-08 | 中国辐射防护研究院 | 一种核素标记的靶向探针及其制备方法和应用 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025058000A1 (ja) * | 2023-09-13 | 2025-03-20 | 東レ株式会社 | 癌の治療、予防及び／又は診断用医薬組成物 |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9345661B2 (en) * | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| EP3148336B1 (en) * | 2014-05-28 | 2019-10-02 | Eisai R&D Management Co., Ltd. | Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer |
| JP6738909B2 (ja) * | 2016-05-27 | 2020-08-12 | アクティニウム ファーマシューティカルズ インコーポレイテッド | 血液悪性疾患を処置するための低用量抗体に基づく方法 |
| FI3478286T3 (fi) * | 2016-06-29 | 2024-03-14 | Tesaro Inc | Menetelmiä munasarjasyövän hoitamiseksi |
| JP6978251B2 (ja) * | 2017-03-03 | 2021-12-08 | アスラン ファーマシューティカルズ ピーティーイー リミテッド | がん治療 |
| CA3059752A1 (en) * | 2017-04-28 | 2018-11-01 | Actinium Pharmaceuticals, Inc. | Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic |
| CN112867512A (zh) * | 2018-09-25 | 2021-05-28 | 意大利国际先进加速器应用有限公司 | 联合疗法 |
| US20220088231A1 (en) * | 2018-12-03 | 2022-03-24 | Fusion Pharmaceuticals Inc. | Radioimmunoconjugates and dna damage and repair inhibitor combination therapy |
-
2020
- 2020-01-02 EP EP20736050.4A patent/EP3906061A4/en active Pending
- 2020-01-02 JP JP2021538752A patent/JP2022516170A/ja active Pending
- 2020-01-02 US US17/419,381 patent/US20220072167A1/en not_active Abandoned
- 2020-01-02 CA CA3125197A patent/CA3125197A1/en active Pending
- 2020-01-02 WO PCT/US2020/012016 patent/WO2020142583A1/en not_active Ceased
-
2024
- 2024-09-17 US US18/887,845 patent/US20250121105A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021120406A5 (ja) | 癌を治療するための組み合わせ物 | |
| Yim et al. | Current management of hepatocellular carcinoma: an Eastern perspective | |
| JP2022017295A5 (enExample) | ||
| JP2022511471A5 (enExample) | ||
| Kudo | Combination cancer immunotherapy in hepatocellular carcinoma | |
| JP2022017296A5 (enExample) | ||
| JP2021063120A5 (enExample) | ||
| Attarbaschi et al. | Outcome of children with primary resistant or relapsed non‐Hodgkin lymphoma and mature B‐cell leukemia after intensive first‐line treatment: a population‐based analysis of the Austrian Cooperative Study Group | |
| Yamazaki et al. | Effects of radiation on tumor vasculature | |
| JP2019506392A5 (enExample) | ||
| JP2020512977A5 (enExample) | ||
| JP2020516693A5 (enExample) | ||
| JP2020531463A5 (enExample) | ||
| JP2024524527A5 (enExample) | ||
| JP2025503971A5 (enExample) | ||
| Kolb et al. | A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia | |
| JP2024016209A5 (enExample) | ||
| Hsieh et al. | Enhanced antitumour response of gold nanostar-mediated photothermal therapy in combination with immunotherapy in a mouse model of colon carcinoma | |
| JP2020517704A (ja) | α線放射免疫療法薬とともにＢＣＬ−２インヒビターを使用してがんを処置するための方法 | |
| JP2021511344A5 (enExample) | ||
| Pochedly | Prophylactic CNS therapy in childhood acute leukemia: Review of methods used | |
| Clement et al. | Influence of WR 2721 on the efficacy of radiotherapy and chemotherapy of murine tumors | |
| Cooper et al. | A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia | |
| JP2024541900A5 (enExample) | ||
| JPH1045589A (ja) | テモゾロミドによる改良されたガンの処置 |